This Article Full Text Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Services Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Konecny, G. Articles by Pegram, M. Search for Related Content PubMed PubMed Citation Articles by Konecny, G. Articles by Pegram, M.

Association of Urokinase-Type Plasminogen Activator and Its Inhibitor with Disease Progression and Prognosis in Ovarian Cancer¹

Division of Hematology-Oncology, Department of Medicine, University of California at Los Angeles, School of Medicine, Los Angeles, California 90095-1678 [G. K., D. S., M. P.], and Departments of Obstetrics and Gynecology [M. U., A. P., R. K., M. G., H. H.] and Clinical Chemistry [P. S.], Klinikum Grosshadern, Ludwig Maximillians Universität München, 81377 München, Germany

Purpose: Urokinase-type plasminogen activator (uPA) and its inhibitor, plasminogen activator inhibitor (PAI)-1, have been shown to be related to poor prognosis in a variety of malignant solid tumors. Studies on the prognostic relevance of uPA and PAI-1 in ovarian cancer, however, have been inconclusive. The current study tests the hypothesis that elevated expression of uPA and PAI-1 is associated with prognosis and disease progression.

Experimental Design: uPA and PAI-1 were prospectively measured by quantitative ELISA in tumor samples from 103 ovarian cancer patients (82 primary invasive epithelial carcinomas, 9 low malignant potential tumors, and 12 recurrent ovarian carcinomas).

Results: uPA but not PAI-1 levels were consistently associated with malignant progression, with levels increased from low malignant potential tumors to primary tumors (uPA, P = 0.04; PAI-1, P = 0.019), from early to advanced disease stages (uPA, P = 0.014; PAI-1, P = 0.23), and from primary to intra-abdominal metastatic tumors (uPA, P = 0.001; PAI-1, P = 0.16). High uPA and PAI-1 levels were associated with residual tumor volumes of >1 cm (P = 0.001 and P = 0.016, respectively). Among invasive International Federation of Gynecologists and Obstetrician stages I–IV tumors, elevated levels of uPA (>5.5 ng/mg) and PAI-I (>18.8 ng/ml) were associated with a shortened progression-free survival (uPA, P = 0.003; PAI-1, P = 0.039) and overall survival (uPA, P = 0.0002; PAI-1, P = 0.007). In multivariate analysis, uPA retained prognostic independence for progression-free survival (P = 0.037) and overall survival (P = 0.006).

Conclusions: These data suggest that the uPA/PAI-1 axis may play an important role in the intra-abdominal spread and reimplantation of ovarian cancer cells. The prognostic relevance of uPA and PAI-1 supports their possible role in the malignant progression of ovarian cancer.

This article has been cited by other articles:

				E. Henic, C. Borgfeldt, I. J. Christensen, B. Casslen, and G. Hoyer-Hansen Cleaved Forms of the Urokinase Plasminogen Activator Receptor in Plasma Have Diagnostic Potential and Predict Postoperative Survival in Patients with Ovarian Cancer Clin. Cancer Res., September 15, 2008; 14(18): 5785 - 5793. [Abstract] [Full Text] [PDF]

				J. Gutierrez, G. E. Konecny, K. Hong, A. Burges, T. D. Henry, P. D. Lambiase, W. Lee Wong, and Y. G. Meng A New ELISA for Use in a 3-ELISA System to Assess Concentrations of VEGF Splice Variants and VEGF110 in Ovarian Cancer Tumors Clin. Chem., March 1, 2008; 54(3): 597 - 601. [Abstract] [Full Text] [PDF]

				S. M. K. Pulukuri, B. Gorantla, and J. S. Rao Inhibition of Histone Deacetylase Activity Promotes Invasion of Human Cancer Cells through Activation of Urokinase Plasminogen Activator J. Biol. Chem., December 7, 2007; 282(49): 35594 - 35603. [Abstract] [Full Text] [PDF]

				J. Dorn, M. Schmitt, R. Kates, B. Schmalfeldt, M. Kiechle, A. Scorilas, E. P. Diamandis, and N. Harbeck Primary Tumor Levels of Human Tissue Kallikreins Affect Surgical Success and Survival in Ovarian Cancer Patients Clin. Cancer Res., March 15, 2007; 13(6): 1742 - 1748. [Abstract] [Full Text] [PDF]

				S. J. C. Shan, A. Scorilas, D. Katsaros, I. Rigault de la Longrais, M. Massobrio, and E. P. Diamandis Unfavorable Prognostic Value of Human Kallikrein 7 Quantified by ELISA in Ovarian Cancer Cytosols Clin. Chem., October 1, 2006; 52(10): 1879 - 1886. [Abstract] [Full Text] [PDF]

				C. A. Borgono, T. Kishi, A. Scorilas, N. Harbeck, J. Dorn, B. Schmalfeldt, M. Schmitt, and E. P. Diamandis Human Kallikrein 8 Protein Is a Favorable Prognostic Marker in Ovarian Cancer Clin. Cancer Res., March 1, 2006; 12(5): 1487 - 1493. [Abstract] [Full Text] [PDF]

				H. Li, X. Ye, C. Mahanivong, D. Bian, J. Chun, and S. Huang Signaling Mechanisms Responsible for Lysophosphatidic Acid-induced Urokinase Plasminogen Activator Expression in Ovarian Cancer Cells J. Biol. Chem., March 18, 2005; 280(11): 10564 - 10571. [Abstract] [Full Text] [PDF]

				B. Karlan Profiling the Perpetrator J. Clin. Oncol., December 1, 2004; 22(23): 4663 - 4664. [Full Text] [PDF]

				D. Spentzos, D. A. Levine, M. F. Ramoni, M. Joseph, X. Gu, J. Boyd, Towia. A. Libermann, and S. A. Cannistra Gene Expression Signature With Independent Prognostic Significance in Epithelial Ovarian Cancer J. Clin. Oncol., December 1, 2004; 22(23): 4700 - 4710. [Abstract] [Full Text] [PDF]

				A. Paju, J. Vartiainen, C. Haglund, O. Itkonen, K. von Boguslawski, A. Leminen, T. Wahlstrom, and U.-H. Stenman Expression of Trypsinogen-1, Trypsinogen-2, and Tumor-Associated Trypsin Inhibitor in Ovarian Cancer: Prognostic Study on Tissue and Serum Clin. Cancer Res., July 15, 2004; 10(14): 4761 - 4768. [Abstract] [Full Text] [PDF]

				G. Gamberi, M. S. Benassi, P. Ragazzini, L. Pazzaglia, F. Ponticelli, C. Ferrari, A. Balladelli, M. Mercuri, M. Gigli, F. Bertoni, et al. Proteases and interleukin-6 gene analysis in 92 giant cell tumors of bone Ann. Onc., March 1, 2004; 15(3): 498 - 503. [Abstract] [Full Text] [PDF]

				A. Scorilas, C. A. Borgono, N. Harbeck, J. Dorn, B. Schmalfeldt, M. Schmitt, and E. P. Diamandis Human Kallikrein 13 Protein in Ovarian Cancer Cytosols: A New Favorable Prognostic Marker J. Clin. Oncol., February 15, 2004; 22(4): 678 - 685. [Abstract] [Full Text] [PDF]

				T. Sakakibara, K. Hibi, Y. Kodera, K. Ito, S. Akiyama, and A. Nakao Plasminogen Activator Inhibitor-1 as a Potential Marker for the Malignancy of Esophageal Squamous Cell Carcinoma Clin. Cancer Res., February 15, 2004; 10(4): 1375 - 1378. [Abstract] [Full Text] [PDF]